Developer docs
API playgroundTry for free, no card

Search company profiles

EmitBio

Full company profile

uuid0003lf1

Namestring
EmitBio
Websiteurl
emitbio.com
Company typeenum
Private
Founded yearint
2020
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMorrisville, United States
HQ citystring
Morrisville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
medical device development, respiratory disease treatment, light technology platform, infectious disease therapy, photomedical devices
Industry3 codes
1Anesthesia & Respiratory Gas Delivery Equipment (Breathing Circuits, Vaporizers, Gas Mixers)
CodeHLAHAGAKPrimaryYes
2Disinfection & Surface Decontamination (Wipes, Sprays, Fogging, UV Robots)
CodeHLAHANADPrimaryNo
3UV Germicidal Light (UV-C) & HVAC Disinfection Systems
CodeHSAOAIAIPrimaryNo
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Irradiation Apparatus Manufacturing334517
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Medical Devices
Social media profiles1 record
Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

EmitBio is a medical device company that utilizes a proprietary light technology platform for respiratory infectious disease. The company is currently in pre-launch status with a 'Coming Soon' website, and no specific product names or detailed service offerings are publicly disclosed.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

EmitBio is a medical device company that offers a proprietary light technology platform for respiratory infectious disease. The company is currently in pre-launch status with a 'Coming Soon' website, and no specific product names, modules, or detailed service offerings are publicly disclosed at this time.

Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
1UV Angel
TypeDirect peer
Description

Developer of UV-C light technology for pathogen decontamination across air and surface applications. Comparable to EmitBio on the core light-based disinfection modality, although UV Angel's primary focus is on facility/ambient settings rather than internal respiratory delivery.

2Aytu BioPharma
TypeEmerging player
Description

Specialty pharmaceutical and consumer health company with a portfolio addressing respiratory infectious disease. Comparable through its respiratory-infectious-disease commercial focus, though its modality is pharmaceutical rather than device-based.

3AquiSense Technologies
TypeDirect peer
Description

Specializes in UV-C LED disinfection systems for water, air, and surface applications. Directly comparable to EmitBio on the underlying UV-C light disinfection mechanism and engineering stack.

4Healthe
TypeDirect peer
Description

Develops UV-C and far-UVC products intended to reduce airborne and surface pathogens in occupied spaces. Comparable to EmitBio through shared UV-light disinfection science and pathogen-reduction claims.

5Spectra254
TypeDirect peer
Description

Manufactures UV-C light disinfection devices for healthcare, laboratory, and commercial environments. Comparable on the UV-light platform and on commercializing pathogen-inactivation claims in regulated settings.

6Lumenis
TypeBroad incumbent
Description

Established medical device company built around light-based energy platforms (laser, IPL) for clinical applications. Comparable as a broader incumbent using light as a therapeutic mechanism, although its focus is largely surgical and aesthetic rather than infectious disease.

7ResMed
TypeBroad incumbent
Description

Global leader in respiratory medical devices and connected care. Comparable as a broad incumbent in the respiratory device category that EmitBio targets, with a vastly larger commercial footprint and established hospital channel.

8Philips Respironics
TypeBroad incumbent
Description

Major respiratory care and sleep therapy device portfolio within Philips. Comparable on the respiratory device category and clinical customer base, though Philips' portfolio is broader and non-light-based.

9Inspire Medical Systems
TypeBroad incumbent
Description

Medical device company commercializing an implantable neurostimulation therapy for obstructive sleep apnea and, increasingly, upper-airway conditions. Comparable as a respiratory/upper-airway medical device incumbent that has scaled from novel modality to commercial success.

10Inogen
TypeBroad incumbent
Description

Medical device company focused on portable oxygen delivery for chronic respiratory disease. Comparable as an established respiratory device specialist with a defined patient and clinician go-to-market motion.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

EmitBio

Medical Devicesemitbio.com

EmitBio firmographics

Firmographics
Name
EmitBio
Website
https://emitbio.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

EmitBio industry classification

Industry
Product category
Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Irradiation Apparatus Manufacturing (334517)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro primary industry
Anesthesia & Respiratory Gas Delivery Equipment (Breathing Circuits, Vaporizers, Gas Mixers) (HLAHAGAK)
akta.pro secondary industries
Disinfection & Surface Decontamination (Wipes, Sprays, Fogging, UV Robots) (HLAHANAD), UV Germicidal Light (UV-C) & HVAC Disinfection Systems (HSAOAIAI)

Keywords

  • Medical device development
  • Respiratory disease treatment
  • Light technology platform
  • Infectious disease therapy
  • Photomedical devices

Where EmitBio is headquartered

Location

Headquarters

HQ city
Morrisville
HQ country
United States
HQ region
North America

Markets served

EmitBio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

EmitBio product offering

Product offering

Core offering

EmitBio is a medical device company that utilizes a proprietary light technology platform for respiratory infectious disease. The company is currently in pre-launch status with a 'Coming Soon' website, and no specific product names or detailed service offerings are publicly disclosed.

Product overview

EmitBio is a medical device company that offers a proprietary light technology platform for respiratory infectious disease. The company is currently in pre-launch status with a 'Coming Soon' website, and no specific product names, modules, or detailed service offerings are publicly disclosed at this time.

Differentiator

Problem solved

Functional benefit

Companies that use EmitBio

Customer profile

Ideal customer profiles1 record

EmitBio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

EmitBio partnerships and signals

Strategic signal

Recent moves1 record

Expansion highlights2 records

EmitBio competitors and assessment

Company assessment

Direct peers

  • UV Angel: Developer of UV-C light technology for pathogen decontamination across air and surface applications. Comparable to EmitBio on the core light-based disinfection modality, although UV Angel's primary focus is on facility/ambient settings rather than internal respiratory delivery.
  • AquiSense Technologies: Specializes in UV-C LED disinfection systems for water, air, and surface applications. Directly comparable to EmitBio on the underlying UV-C light disinfection mechanism and engineering stack.
  • Healthe: Develops UV-C and far-UVC products intended to reduce airborne and surface pathogens in occupied spaces. Comparable to EmitBio through shared UV-light disinfection science and pathogen-reduction claims.
  • Spectra254: Manufactures UV-C light disinfection devices for healthcare, laboratory, and commercial environments. Comparable on the UV-light platform and on commercializing pathogen-inactivation claims in regulated settings.

Emerging players

  • Aytu BioPharma: Specialty pharmaceutical and consumer health company with a portfolio addressing respiratory infectious disease. Comparable through its respiratory-infectious-disease commercial focus, though its modality is pharmaceutical rather than device-based.

Broad incumbents

  • Lumenis: Established medical device company built around light-based energy platforms (laser, IPL) for clinical applications. Comparable as a broader incumbent using light as a therapeutic mechanism, although its focus is largely surgical and aesthetic rather than infectious disease.
  • ResMed: Global leader in respiratory medical devices and connected care. Comparable as a broad incumbent in the respiratory device category that EmitBio targets, with a vastly larger commercial footprint and established hospital channel.
  • Philips Respironics: Major respiratory care and sleep therapy device portfolio within Philips. Comparable on the respiratory device category and clinical customer base, though Philips' portfolio is broader and non-light-based.
  • Inspire Medical Systems: Medical device company commercializing an implantable neurostimulation therapy for obstructive sleep apnea and, increasingly, upper-airway conditions. Comparable as a respiratory/upper-airway medical device incumbent that has scaled from novel modality to commercial success.
  • Inogen: Medical device company focused on portable oxygen delivery for chronic respiratory disease. Comparable as an established respiratory device specialist with a defined patient and clinician go-to-market motion.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

EmitBio social profiles

Digital presence

EmitBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

EmitBio leadership team

Management profile

Number of profiles

EmitBio funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

EmitBio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EmitBio

What does EmitBio do?

EmitBio is a medical device company that utilizes a proprietary light technology platform for respiratory infectious disease. The company is currently in pre-launch status with a 'Coming Soon' website, and no specific product names or detailed service offerings are publicly disclosed.

When was EmitBio founded?

EmitBio was founded in 2020. It employs 11 to 50 people.

Where is EmitBio based?

EmitBio is headquartered in Morrisville, United States, in the North America region.

Who are EmitBio's main competitors?

Direct peers on record are UV Angel, AquiSense Technologies, Healthe and Spectra254. Aytu BioPharma is listed as an emerging player. Broad incumbents are Lumenis, ResMed, Philips Respironics, Inspire Medical Systems and Inogen.

Does EmitBio have an API?

No public API is recorded for EmitBio.

What industry is EmitBio in?

EmitBio's product category is Medical Devices. Its primary akta.pro industry code is HLAHAGAK, Anesthesia & Respiratory Gas Delivery Equipment (Breathing Circuits, Vaporizers, Gas Mixers), with a secondary code of HLAHANAD, Disinfection & Surface Decontamination (Wipes, Sprays, Fogging, UV Robots). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireEmitBio™ Granted Biotech Patent Covering Light to Treat COVID-19 and other DiseasesEmitBio, Inc., a biotechnology company based in Durham, North Carolina, has been granted U.S. patent 11,147,984 covering oral devices that use visible light to limit or eliminate pathogens including SARS-CoV-2, the virus causing COVID-19. The patent, issued through the USPTO's COVID-19 Prioritized Examination Pilot Program in less than a year from filing, extends intellectual property protection through 2040 and was accompanied by a peer-reviewed publication in Scientific Reports demonstrating blue light's ability to inhibit coronavirus replication in human tissue without damaging tissue. The company, a subsidiary of KNOW Bio LLC, states this represents a fraction of its completed development program targeting respiratory infections and airway inflammation as an alternative to conventional vaccine, antibody, and antiviral approaches.PR NewswireResultados da EmitBio oferecem uma redução de 99,99% da variante Delta em tecido humanoEmitBio, Inc. announced successful results from an in vitro neutralization study demonstrating that its visible light technology eliminated 99.99% of the SARS-CoV-2 Delta variant in human respiratory tissue without damaging healthy tissue after three days of twice-daily dosing. The company had previously shown in a human clinical study that the technology reduced viral load by 99.9% and accelerated symptom resolution by more than two days in adults with mild to moderate COVID-19. The device remains in the research phase and requires regulatory approval before becoming commercially available.PR NewswireLos resultados de EmitBio ofrecen una reducción del 99,99% de la variante Delta en tejido humanoEmitBio, Inc., a life sciences company based in Durham, North Carolina, announced successful results from an in vitro neutralization study showing its visible light technology eliminated 99.99% of the SARS-CoV-2 Delta variant in human respiratory tissue without damaging healthy tissue after three days of daily dosing. The company's investigational device, designed for at-home COVID-19 self-treatment, previously reduced viral load in saliva by 99.9% and accelerated symptom resolution by more than two days in its first human trial, with a third human trial now underway. Subject to regulatory approval, EmitBio positions this technology as a potential prophylactic and treatment option for both unvaccinated individuals and vaccinated patients experiencing recurrent infections.PR NewswireEmitBio taps Technology Public Relations Veteran James PearsonEmitBio Inc., a life science company headquartered in Durham, North Carolina, announced the appointment of James A. Pearson as Head of Global Public Relations, a newly created position to lead global PR and strategic communications. EmitBio has developed an in-home prescription device using precise wavelengths of light technology that demonstrated over 99.9% reduction in MERS-CoV viral load in laboratory settings and is currently seeking FDA authorization through an EUA to combat COVID-19 and its variants. The company's parent company, KNOW Bio LLC, has raised more than $70 million since 2017, and the appointment represents EmitBio's strategic effort to expand its media presence as it progresses toward potential market authorization.PR NewswireEmitBio Treatment Broadly Effective Against Coronavirus VariantsEmitBio Inc. announced new evidence that its proprietary light technology can inactivate the UK and South Africa variants of SARS-CoV-2, achieving greater than 99.9% reduction in viral load in controlled laboratory tests at doses safe to human tissue. The company has submitted clinical trial results along with Phase I safety data to the FDA requesting Emergency Use Authorization for its investigational hand-held device designed for at-home treatment of mild-to-moderate COVID-19 in adults. The treatment's mechanism of action is not dependent on SARS-CoV-2 genetics or viral spike protein configuration, making it potentially effective against currently circulating and future variants.PR NewswireEmitBio Demonstrates Statistically Significant Results In Clinical Trial For COVID-19 TreatmentEmitBio Inc. announced on February 17, 2021 statistically significant efficacy results from its randomized, placebo-controlled, double-blind Phase I/II trial of a visible-light device that targets the back of the throat for at-home COVID-19 treatment. Treated subjects cleared symptoms in a median 104 hours versus 161 hours in controls, and had a median log10 viral load of 0.00 versus 3.17 after seven days. The company submitted the results plus Phase I safety data to the FDA for Emergency Use Authorization.PR NewswireEmitBio Demonstrates New Treatment Is Effective Against Multiple Types Of CoronavirusEmitBio Inc. announced on Feb. 4, 2021 that laboratory testing showed its proprietary visible light technology reduced MERS-CoV viral load by more than 99.9% at doses safe for human tissue, alongside SARS-CoV-2. The company says the results suggest effectiveness against SARS-CoV-2 variants and other coronaviruses, and its investigational hand-held device is not yet available for sale pending FDA action.PR NewswireEmitBio Announces Positive Clinical Results Supporting A Novel Therapeutic For COVID-19EmitBio Inc. announced clinical trial results for its investigational light-based COVID-19 treatment device, reporting a 99.9% average viral load reduction and symptom resolution accelerated by more than 48 hours compared to the control group in a placebo-controlled, randomized double-blind study. The handheld device, which uses precise wavelengths of safe visible light directed to the back of the throat, showed no treatment-related adverse events, and the company has submitted results to the FDA requesting Emergency Use Authorization. The company aims to provide an at-home treatment option for adults with mild-to-moderate COVID-19 as a public health intervention.